REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

PHASE3CompletedINTERVENTIONAL
Enrollment

517

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

July 31, 2011

Conditions
Multiple Sclerosis
Interventions
DRUG

RNF

Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.

DRUG

RNF

Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.

DRUG

Placebo

Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.

Trial Locations (67)

Unknown

Research Site, Mendoza

Research Site, Sydney

Research Site, Graz

Research Site, Innsbruck

Research Site, B-Leuven

Research Site, Bruges

Research Site, Pleven

Research Site, Rousse

Research Site, Shumen

Research Site, Sofia

Research Site, Varna

Research Site, Montreal, Quebec

Research Site, Ontario

Research Site, Victoria British Columbia

Research Site, Karlovac

Research Site, Osijek

Research Site, Rijeka

Research Site, Split

Research Site, Zagreb

Research Site, Hradec Králové

Research Site, Olomouc

Research Site, Prague

Research Site, Tallinn

Research Site, Tartu

Research Site, OYS

Research Site, Vantaa

Research Site, Paris

Research Site, Poissy

Research Site, Hanover

Research Site, Henningsdorf

Research Site, Munich

Research Site, Athens

Research Site, Ness Ziona

Research Site, Safed

Research Site, Tel Litwinsky

Research Site, Catania

Research Site, Milan

Research Site, Padua

Research Site, Roma

Research Site, Riga

Research Site, Beirut

Research Site, Rabat

Research Site, Bialystok

Research Site, Lodz

Research Site, Warsaw

Research Site, Wroclaw

Research Site, Lisbon

Research Site, Bucharest

Research Site, Iași

Research Site, Târgu Mureş

Research Site, Timișoara

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Novosibirsk

Research Site, Saint Petersburg

Research Site, Samara

Research Site, Saratov

Research Site, Yekaterinburg

Research Site, Riyadh

Research Site, Belgrade

Research Site, Niš

Research Site, Prešov

Research Site, Barcelona

Research Site, Bilbao

Research Site, Madrid

Research Site, Seville

Research Site, Istanbul

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT00404352 - REbif FLEXible Dosing in Early Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter